Ono Pharmaceutical Co., Ltd.

Toray Industries, Inc.

Ono Pharmaceuticals Co., Ltd.

Kanji Takahashi

Nobuyuki Hamanaka

Hidekado Tokumoto

Tsuneyuki Sugiura

Masanobu Uyama

Jun Utsumi

Saburo Sone

Atsushi Kijima

Hiroshi Ohkuma

Takao Tobe

Aminobutylic acid derivatives of the formula (I):wherein the symbols are as defined in specification; and non-toxic salts thereof. Because of inhibiting matrix metalloproteinase, the compounds of the formula (I) are useful for prevention and/or treatment of diseases, for example, rheumatoid diseases, arthrosteitis, osteoarthritis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, cornea ulcer, metastasis, invasion or growth of tumor cells, autoimmune disease, disease caused by vascular emigration or infiltration of leukocytes, arterialization, multiple sclerosis, arota aneurysm, endometriosis, restenosis after PTCA, unstable angina, acute myocardial infarction, transient ischemic attack.

Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient

4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient

Aminobutyric acid derivatives

Pharmaceutical composition containing aryl (sulfide, sulfoxide, sulfone) derivatives of the formula (1) and the salts thereof as active ingredient (wherein R,is H, alkyl; R,is COOR,, CONHOR,; E is &mdash;CONR,&mdash;, &mdash;NR,CO&mdash;, &mdash;OCO&mdash;,&mdash;COO&mdash;, &mdash;CH,&mdash;O&mdash;, &mdash;(CH,),&mdash;, vinylene, ethynylene; J is bond, alkylene; A is H, alkyl, Ar, alkyl-OH ; R,, R,is H, alkyl, COOR,, hydroxy, &mdash;NR,R,,

Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient

Use of interferon-.beta. or .gamma. to treat retinal edema

Fused benzeneoxyacetic acid derivatives of the formula (I): ##STR1## or salts thereof possess an agonistic effect on the PGI.sub.2 receptor and thus are useful for preventing and/or treating thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertension. A, B, D, and R.sup.1 are as defined in the specification.

Fused benzeneoxyacetic acid derivatives

We proposed a novel compound having an activity of PGI.sub.2 receptor agonist. A phenoxyacetic acid derivative of the formula ##STR1## A is --C(R.sup.1).dbd.N.about.OR.sup.2, --CH(R)NH--OR.sup.2, --COE, --SO.sub.2 E, --CH.sub.2 --NR.sup.3 --Y, --Z--NR.sup.3 --CONR.sup.4 R.sup.5, --CH.sub.2 --OR.sup.6, --CO.sub.2 R.sup.6, --CH.sub.2 --O.about.N.dbd.CR.sup.7 R.sup.8, --CH.sub.2 --O--NHCHR.sup.7 R.sup.8, substituted by imidazolyl(methyl), pyrazolylmethyl, oxazolyl(methyl), thioxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolylmethyl;

Phenoxyacetic acid derivatives

A fused benzeneoxyacetic acid derivative of the formula (I): ##STR1## wherein D is a 3-5-membered ring; B is a C.sub.1-4 group; R.sup.1 is OH alkoxy, (alkyl) amino, residue of an amino acid; A is phenyl, alkyl substituted by phenyl, residue of an imidazole, imidazole-2-yloxy(thio), 2-oxoimidazole, pyrazole, oxadiazole, oxazole, trizole, isoxazole or isothiazole, in the group of benzene may be substituted by one to three of alkyl, alkoxy, halogen, nitro or trihalomethyl; and salts thereof possess an agonistic effect on the PGI.sub.2 receptor, so is useful for prevention and/or treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertension.

Fused benzeneoxyacetic acid derivatives which have PGI.sub.2 receptor

A pharmaceutical composition for use as a retinal pigment epithelial cell growth stimulating agent comprising an interferon and a pharmaceutically acceptable carrier is disclosed. The composition is useful as a therapeutic agent for oculopathies, such as pigmentary retinal degeneration, central chorioretinopathy, and macular dystrophy.

Pharmaceutical composition for use as a retinal pigment epithelial cell

A fused benzeneoxyacetic acid derivative of the formula (I): ##STR1## A is --COW, --NR.sup.4 --Y or --Z--NR.sup.4 --CONR.sup.2 R.sup.3 ; and salts thereof possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertention.

A fused benzeneoxyacetic acid derivative of the formula (I): ##STR1## where the substituents are defined in the specification and salts thereof possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclerosis, inchemic heart diseases, gastric alcer and hypertension.

Triazolyl-phenoxyacetic acid compounds which have useful pharmaceutical

An oxime derivative (I): ##STR1## that D ring and B bonding to D ring are (i)-(iv), wherein R.sup.1 is hydrogen, lower alkyl; R.sup.2 is hydrogen, alkyl, phenyl, cycloalkyl, monocyclic ring containing nitrogen, lower alkyl substituted by benzene ring or cycloalkyl, lower alkyl substituted by monocyclic ring containing nitrogen; R.sup.3 is alkyl, phenyl, cycloalkyl, monocyclic ring containing nitrogen, lower alkyl substituted by benzene ring or cycloalkyl, lower alkyl substituted by monocyclic ring containing nitrogen; e is 3-5, f is 1-3, p is 1-4, q is 1-2, r is 1-3; the position of the bond to D ring in (iii) and (iv) is a or b, and the ring in R.sup.2 and R.sup.3 may be substituted by lower alkyl, alkoxy, halogen, nitro, trihalomethyl; and salts thereof, possess an agonistic activity on PGl2 receptor, and therefore are useful for prevention and/or treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer and hypertension.

Oxime derivative

A fused benzeneoxyacetic acid derivative of the formula: ##STR1## wherein ##STR2## is (i) ##STR3## (ii) ##STR4## (iii) ##STR5## or (iv) ##STR6## A is (i) ##STR7## or (ii) ##STR8## R.sup.1 is hydrogen or C.sub.1-4 alkyl; R.sup.2 is hydrogen, C.sub.1-6 alkyl or phenyl;

Growing community of inventors

Osaka, Japan

Kanji Takahashi